Talphera, Inc.的封面图片
Talphera, Inc.

Talphera, Inc.

制药业

San Mateo,California 3,620 位关注者

Focused on the development and commercialization of innovative therapies for use in medically supervised settings

关于我们

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra?, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. To learn more about the development status of these product candidates, please visit our website at www.talphera.com.

网站
https://www.talphera.com
所属行业
制药业
规模
51-200 人
总部
San Mateo,California
类型
上市公司
创立
2005
领域
pharmaceuticals、research & development和pain management

地点

  • 主要

    1850 Gateway Dr

    US,California,San Mateo,94404

    获取路线

Talphera, Inc.员工

相似主页

查看职位

融资

Talphera, Inc. 共 12 轮

上一轮

上市后股权

US$6,000,000.00

Crunchbase 上查看更多信息